The purpose of this study was to examine the outcomes of patients who developed coronary in-stent restenosis (ISR) or stent thrombosis (STH) inside drug-eluting stents (DES).
Despite the marked decrease in major adverse cardiovascular events (MACE) attributable to drug-eluting stents (DES), in-stent restenosis (ISR) and stent thrombosis (STH) remain important clinical challenges. The "stent sandwich" technique (stent within a stent) has been applied with mixed results for restenosis after bare-metal stenting (BMS) (1) (2) (3) (4) . Little information is available, however, regarding the long-term results of this technique for ISR or STH of DES. We present our observations in consecutive patients who developed one of these adverse events after DES implantation.
Patient Population and Methods
We identified 92 consecutive patients who developed ISR (n ϭ 84) or STH (n ϭ 8) after DES implantation. All patients had received aspirin, 325 mg, before the initial procedure, followed by Ն75 mg daily indefinitely, along with clopidogrel or ticlopidine for Ն6 months.
The "homo-stent sandwich" technique consisted of restenting with the same DES, "hetero-stent sandwich" with a different DES, and "other" techniques included balloon angioplasty, insertion of a BMS, or brachytherapy. In-stent restenosis was defined as a Ͼ50% diameter stenosis within the first DES, or within 5 mm of its edges. The morphology of restenotic lesions has been described elsewhere (5) . Major adverse cardiac events included death from all causes, myocardial infarction (MI), or target lesion revascularization (TLR). Myocardial infarction was defined as chest pain accompanied by new electrocardiographic changes consistent with ischemia and a creatine kinase (CK)-MB concentration Ͼ3-fold the upper normal limit. Target lesion revascularization was defined as re-intervention on the stented segment for chest pain or Ͼ70% stenosis on follow-up angiogram. Stent thrombosis was defined as an intraluminal filling defect with contrast staining on 3 sides, representing total or partial stent occlusion, present at the time of a clinically driven, repeat angiography. Patients were followed clinically at 6 months, and 1 and 2 years. Table 1 . Patients who developed ISR/STH were more likely to be persons with diabetes, hypertensive and hypercholesterolemic, more often had histories of MI, prior coronary artery bypass graft surgery, or percutaneous coronary intervention (PCI), and had a lower prevalence of non-STsegment elevation myocardial infarction (STEMI) and higher prevalence of unstable angina at presentation.
The clinical and angiographic characteristics, and the indications for repeat PCI among the 92 patients, and among the 3 treatment subgroups, are shown in Table 2 . Except for a higher prevalence of prior congestive heart failure in the "Others," these subgroups were similar. Three patients required 2 procedures during separate admissions for DES ISR in separate lesions. Clopidogrel was administered for an average of 14.6 Ϯ 6.1 months.
Stent thrombosis occurred in 8 patients and resulted in STEMI in 6. Five patients had early STH within 30 days of implantation, and 3 had late STH after 180 days. Among these 6 STEMI patients, 1 died of MI at 212 days and 1 had recurrent STH at 71 days of follow-up. Two non-STEMI patients who had undergone repeat PCI for STH that occurred within 30 days of initial DES placement died in renal failure and cardiogenic shock, at 4 and 8 days, respectively, after the stent sandwich procedure.
Outcome data were available for 91 patients (99%). Over a mean follow-up of 15.0 Ϯ 6.0 months, the overall rates of death, MI, and TLR were 8.7%, 2.2%, and 30.6%, respectively. The cumulative rates of in-hospital, 6-month, and 12-month adverse clinical events are summarized in Table 3 . Recurrent restenosis recurred in 28 patients (30.4%) and 33 lesions (30.6%). Of 6 patients who died after hospital discharge, 3 died of MI at 19, 105, and 212 days, respectively, 1 died of end-stage heart failure at 718 days, 1 died of respiratory failure at 511 days, and 1 died of unknown cause at 219 days of follow-up. Outcomes among treatment subgroups were statistically similar, although the "hetero-stent" treatment group tended to have lower MACE rates and need for repeat revascularization at 12 months.
Discussion
Although stent sandwich has mostly replaced brachytherapy, there is a paucity of data regarding treatments and outcomes in patients with DES restenosis. In contrast with the disappointing results of the RIBS (Restenosis Intrastent: Balloon angioplasty versus elective Stenting) study, where BMS ISR was treated with another BMS, the stent sandwich technique was superior to balloon angioplasty for the treatment of BMS ISR in the ISAR-DESIRE (Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs. Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis) study (6) , and other studies have shown promising results with DES implanted for BMS ISR (3, 4, (7) (8) (9) . Ours is the first report of the "real-world" performance of stent sandwich in a consecutive series of patients with DES ISR.
In the BMS era, STH was a rare event. It is noteworthy that 8 patients (8.7% of the study population) presented with STH, and that 4 (66.7%) either died or suffered recurrence of STH. This observation highlights recent reports suggesting that DES might be associated with a higher risk of STH, perhaps due to the polymer platform, delayed endothelization, or positive remodeling (10 -15) . Regardless of the underlying mechanism, it should be emphasized that DES patients who experience thrombotic events are probably at higher risk of recurrent STH, with its catastrophic consequences, than ISR. The major adverse cardiovascular event rate, including overall mortality, was high in this population and could not be attributed to small vessel size (data not shown). However, patients who had MACE during follow-up had a higher proportion of saphenous vein graft and a lower percentage of edge restenosis. Tentative explanations for the high MACE rate after stent sandwich include: 1) enhanced allergic or inflammatory responses to the polymer or the drug; 2) excessive intimal hyperplastic response inadequately blocked by the drug or amount of drug delivered; 3) insufficient expansion or improper placement of the stent; and 4) individual predisposition to exaggerated neointimal hyperplasia.
Although the difference was not statistically significant, the hetero-stent treatment group tended to have more All differences among study groups are statistically non-significant. *Three patients underwent 2 separate procedures for in-stent restenosis of different lesions; †total number of lesions ϭ 108. CI ϭ confidence interval; MACE ϭ major adverse cardiac events.
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